Improved Detection of Fibrotic Nonalcoholic Fatty Liver Disease in Community-Based Referrals

被引:0
作者
Piao, Cindy [1 ,2 ]
Arteaga, Elvis J. [1 ]
Chen, Shuai [3 ]
Guo, Aili [1 ,4 ]
Macdonald, Scott T. [1 ,5 ]
Sarkar, Souvik [1 ,2 ,6 ]
机构
[1] Univ Calif Davis, Dept Internal Med, Davis, CA USA
[2] Univ Calif Davis, Div Gastroenterol & Hepatol, Davis, CA USA
[3] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA USA
[4] Univ Calif Davis, Div Endocrinol Diabet & Metab, Davis, CA USA
[5] Univ Calif Davis, Clin Informat, Davis, CA USA
[6] Intercoastal Med Grp, Gastroenterol & Hepatol, 3333 Cattlemen Rd, Sarasota, FL 34232 USA
关键词
NAFLD; NASH; diabetes; fibrosis; FIB-4; community; NAFLD;
D O I
10.1089/met.2023.0092
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease with increasing rates globally. Patients with type 2 diabetes mellitus have higher risk of developing NAFLD. Patients with a higher degree of liver fibrosis in NAFLD are at an increased risk for liver-related mortality, but get missed easily during the referral process. This project aims to improve early detection and linkage-to-care of fibrotic NAFLD patients. Methods: We utilized a combination of automated electronic health record (EHR)-based fibrosis (FIB)-4 score and directed provider education. A health-system wide FIB-4 score calculator that providers can easily add to their workflow for NAFLD patient triaging. Data were analyzed at 6 and 12 months after implementation. Results: Postimplementation, there was an increase in patients referred to hepatology with higher degree of liver fibrosis and decreased referral to hepatology with low risk of liver fibrosis, measured by FIB-4 score. At baseline, similar to 55% of referred patient to hepatology had FIB-4 score <1.3 compared to 38% at 12 months postimplementation. There was an increase in referral of patients with FIB-4 scores >1.3 when compared to preinterventions, 62% versus 45%. This is most pronounced in patients with severe fibrotic disease with FIB-4 score >2.67, 30% versus 12%. Conclusions: Automated FIB-4 score in EHR can improve appropriate linkage-to-care for at-risk fibrotic NAFLD, especially when coupled with targeted provider education. The durability of such improvement is essential to study along with the need to increase broad acceptance across health systems.
引用
收藏
页码:475 / 478
页数:4
相关论文
共 50 条
  • [21] Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease
    Schaapman, Jelte J.
    Tushuizen, Maarten E.
    Coenraad, Minneke J.
    Lamb, Hildo J.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2021, 53 (06) : 1623 - 1631
  • [22] Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
    Arab, Juan Pablo
    Arrese, Marco
    Trauner, Michael
    ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13, 2018, 13 : 321 - 350
  • [23] Nonalcoholic fatty liver disease in asymptomatic obese women
    Rodriguez-Hernandez, Heriberto
    Cervantes-Huerta, Miriam
    Luis Gonzalez, Jose
    Dolores Marquez-Ramirez, Maria
    Rodriguez-Moran, Martha
    Guerrero-Romero, Fernando
    ANNALS OF HEPATOLOGY, 2010, 9 (02) : 144 - 149
  • [24] An update on nonalcoholic fatty liver disease
    Provencher, Daniel M.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2014, 27 (07): : 18 - 22
  • [25] Nonalcoholic fatty liver disease and atherosclerosis
    Eugenio Gaudio
    Valerio Nobili
    Antonio Franchitto
    Paolo Onori
    Guido Carpino
    Internal and Emergency Medicine, 2012, 7 : 297 - 305
  • [26] PPARs and nonalcoholic fatty liver disease
    Liss, Kim H. H.
    Finck, Brian N.
    BIOCHIMIE, 2017, 136 : 65 - 74
  • [27] Nonalcoholic Fatty Liver Disease Foreword
    Day, Christopher P.
    Anstee, Quentin M.
    SEMINARS IN LIVER DISEASE, 2015, 35 (03) : 203 - 205
  • [28] Advances in nonalcoholic fatty liver disease
    Moreno Sanchez, Diego
    MEDICINA CLINICA, 2009, 133 (07): : 258 - 260
  • [29] Nonalcoholic fatty liver disease and diabetes
    Bellini, Maria Irene
    Urciuoli, Irene
    Del Gaudio, Giovanni
    Polti, Giorgia
    Iannetti, Giovanni
    Gangitano, Elena
    Lori, Eleonora
    Lubrano, Carla
    Cantisani, Vito
    Sorrenti, Salvatore
    D'Andrea, Vito
    WORLD JOURNAL OF DIABETES, 2022, 13 (09) : 668 - 682
  • [30] Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
    Arrese, Marco
    Arab, Juan P.
    Barrera, Francisco
    Kaufmann, Benedikt
    Valenti, Luca
    Feldstein, Ariel E.
    SEMINARS IN LIVER DISEASE, 2021, 41 (04) : 421 - 434